BAP31 Lentiviral Activation Particles (h): sc-402421-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- BAP31 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- BAP31 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by BAP31 Lentiviral Activation Plasmid (h) and BAP31 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the BCAP31 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: BAP31 Antibody (D-6): sc-393810
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAP31 Lentiviral Activation Particles (h) | sc-402421-LAC | 200 µl | $455.00 | |||
BAP31 Lentiviral Activation Particles (h2) | sc-402421-LAC-2 | 200 µl | $455.00 |
BCAP31 encodes BAP31, an integral endoplasmic reticulum (ER) membrane chaperone that coordinates membrane protein biogenesis, ER quality control, and vesicular trafficking between the ER and Golgi. BAP31 participates in the handling and export of nascent client proteins and links ER homeostasis to apoptotic signaling through interactions that influence caspase activation and mitochondrial pathways. Through its roles in proteostasis and intracellular transport, BCAP31 is frequently studied in the context of cellular stress responses, immune-related signaling, and regulated cell death. Dysregulation of ER-associated folding and trafficking processes involving BAP31 has been associated with pathophysiological states where proteotoxic stress and aberrant apoptosis are implicated.
BAP31 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient BCAP31 upregulation across a broader range of human cell types.
BAP31 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the BCAP31 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous BAP31 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native BCAP31 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.